Stay updated on Intravenous Prasinezumab in Early Parkinson's Disease Clinical Trial
Sign up to get notified when there's something new on the Intravenous Prasinezumab in Early Parkinson's Disease Clinical Trial page.

Latest updates to the Intravenous Prasinezumab in Early Parkinson's Disease Clinical Trial page
- Check6 days agoChange DetectedA site-wide notice about a lapse in government funding was added, informing users that information may not be up to date and directing them to cc.nih.gov and opm.gov; To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check13 days agoChange Detected- Show glossary option and color-coded change indicators (green for additions, red for deletions) on the Record History page. A new revision label (Revision: v3.4.0) is displayed to reflect the update.SummaryDifference0.6%

- Check20 days agoChange DetectedRevision: v3.3.4 replaces the previous v3.3.3 on the page, indicating a minor update to the site’s version history. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check42 days agoChange DetectedA new history entry on 2025-12-26 adds a Study Status update (version 48). A prior entry from 2025-12-02 was removed.SummaryDifference0.2%

- Check49 days agoChange DetectedFooter changes include a new Revision: v3.3.3 in the page header/footer and removal of the HHS Vulnerability Disclosure link (and related Revision: v3.3.2) on the page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check63 days agoChange DetectedResults have been posted for NCT04777331, including the Outcome Measures (Results). The Study Status has been updated, and the page now displays the results section alongside the existing study details.SummaryDifference0.4%

Stay in the know with updates to Intravenous Prasinezumab in Early Parkinson's Disease Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Intravenous Prasinezumab in Early Parkinson's Disease Clinical Trial page.